Nektar's Rezpegaldesleukin Shows Significant Efficacy in Treating Alopecia Areata

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: 1 hour ago

0mins

NKTR+16.83%

Should l Buy NKTR?

Source: Newsfilter

Clinical Trial Results: In Nektar Therapeutics' REZOLVE-AA study, 29% and 31% of patients in the 18 µg/kg and 24 µg/kg dose groups achieved a SALT score ≤20, demonstrating significant clinical efficacy and indicating the drug's potential in treating severe alopecia areata.
High Completion Rate: 94% of patients completed the 52-week treatment extension, indicating excellent tolerability of the drug, with no severe adverse events reported during long-term use, thereby enhancing its market prospects.
Good Safety Profile: Throughout the 52-week treatment, nearly all treatment-related adverse events were mild to moderate, with most resolving within five days, confirming that the safety profile of Rezpegaldesleukin is consistent with previously reported results.
Broad Market Potential: As the first IL-2 pathway agonist, Rezpegaldesleukin could emerge as the treatment of choice for alopecia areata, particularly given the limited existing treatment options, addressing the urgent need for new therapies among patients.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy NKTR?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on NKTR

Wall Street analysts forecast NKTR stock price to rise

8 Analyst Rating

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 84.860

Low

102.00

Averages

123.43

High

165.00

Current: 84.860

Low

102.00

Averages

123.43

High

165.00

Citi

Buy

maintain

$123

2026-04-07

Reason

Citi

Price Target

$123

AI Analysis

2026-04-07

maintain

Buy

Reason

Citi added an \"upside 30-day catalyst watch\" on shares of Nektar while keeping a Buy rating on the name with a $123 price target. The firm believes the extension data for rezpegaldesleukin in alopecia areata later this morning could drive meaningful upside in the shares. A positive SALT20 response rate in line with low-dose baricitinib of 21%-25% is achievable, the analyst tells investors in a research note.

Wedbush

Neutral

initiated

$70

2026-03-24

Reason

Wedbush

Price Target

$70

2026-03-24

initiated

Neutral

Reason

Wedbush initiated coverage of Nektar with a Neutral rating and $70 price target. The firm believes the company's ongoing trials in alopecia areata and type 1 Diabetes "offer downside protection" for the shares. While rezpegaldesleukin's efficacy in asthma could differentiate the drug from competitors in atopic dermatitis, until Nektar pursues a development in asthma Wedbush sees limited validity for available patient-reported outcome data, the analyst tells investors in a research note. The firm says its price target reflects a sum-of-parts valuation for each of Nektar's clinical programs.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NKTR

Unlock Now

About NKTR

Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Nektar Therapeutics to Review Phase 2b REZOLVE-AA Trial Results on April 20, 2026

20 hours agoNewsfilter

Clinical Trial Update: Nektar Therapeutics will host an investor call on April 20, 2026, to review the 52-week topline results from the ongoing REZOLVE-AA clinical trial, showcasing its potential in treating severe-to-very-severe alopecia areata, which is expected to positively impact the company's stock price.
Therapeutic Innovation: The trial evaluates rezpegaldesleukin, a novel regulatory T-cell proliferator aimed at addressing the underlying immunological dysfunction in autoimmune diseases, and positive results could significantly enhance Nektar's competitive position in the biopharmaceutical sector.
Investor Engagement: Investors can participate in the live webcast, where Nektar will release a press statement and presentation slides, ensuring transparency and boosting investor confidence, which is likely to attract more attention and investment.
Future Outlook: Nektar's pipeline includes multiple clinical trials, and favorable results from the REZOLVE-AA trial could lay the groundwork for future financing and market promotion, further advancing its strategic positioning in immunotherapy.

Nektar Therapeutics Reports Positive Phase 2b Data for Alopecia Areata Treatment

1 hour agoseekingalpha

Clinical Trial Results: Nektar Therapeutics' Phase 2b REZOLVE-AA study demonstrated significant clinical improvements with its lead asset rezpegaldesleukin, as 52-week data revealed that nearly 26% and 28% of patients achieved a SALT Score ≤20 in low and high dose groups, respectively, compared to 15% and 16% at Week 36, indicating a marked enhancement in treatment efficacy.
Market Reaction: Following the announcement, Nektar's shares surged approximately 22%, reflecting strong investor confidence in the drug's potential and indicating a positive outlook for its future commercialization prospects in the competitive biopharmaceutical landscape.
Safety and Tolerability: Over the 52-week treatment period, rezpegaldesleukin exhibited a favorable safety and tolerability profile, with no trial discontinuations due to treatment-emergent adverse events during the extension phase, thereby reinforcing its clinical applicability and market viability.
Future Development Plans: Nektar plans to present REZOLVE-AA data at an upcoming medical event, supporting the late-stage development of rezpegaldesleukin and demonstrating the company's commitment to ongoing investment and market expansion in the alopecia areata treatment space.

Nektar's Rezpegaldesleukin Shows Significant Improvement in Alopecia Treatment

1 hour agoPRnewswire

Clinical Trial Results: In Nektar Therapeutics' REZOLVE-AA study, 29% and 31% of patients in the 18 µg/kg and 24 µg/kg dose groups achieved a SALT score ≤20, demonstrating significant clinical efficacy and indicating the drug's potential in treating severe alopecia.
High Patient Completion Rate: 94% of patients completed the 52-week treatment extension, reflecting excellent tolerability and patient adherence, which lays a solid foundation for future market adoption.
Good Safety Profile: Throughout the 52-week treatment, nearly all adverse events were mild to moderate, with no patients discontinuing treatment due to adverse events, suggesting that Rezpegaldesleukin could be a safe new option for alopecia treatment.
Broad Market Potential: The success of Rezpegaldesleukin could transform the management of alopecia, especially given the limited existing treatment options, addressing the urgent need for new therapies and presenting significant market opportunities.